JPS6210018A - Composition for suppressing obesity - Google Patents

Abstract

PURPOSE:To obtain the titled composition by compounding soya protein and saponin at a specific ratio as active components. CONSTITUTION:Soya protein (powder containing >=90% protein component) and saponin are used as active components, and compounded at a weight ratio of 100:5-25 to obtain the objective obesity-suppressing composition effective to suppress or cure the obesity. It is used in the form of powder, granule, tablet or capsule. The agent can be administered by adding to cake, bread, daily product, soya milk and various other processed foods. Soya saponin can be produced industrially by extracting soybean with a solvent such as alcohol, and a crude saponin having a saponin content of about 45% and containing the same amount of oligosaccharide is used in the present composition.

Description

Detailed Description of the Invention (Field of Industrial Application) The present invention is a composition containing protein isolated from soybeans and saponin isolated from soybeans, which can be ingested by ordinary humans to improve lipid metabolism. The present invention relates to a composition that can suppress and eliminate obesity.

(Prior Art) Obesity is one of the causes of many adult diseases including heart disease, and has become a major health problem for the nation.

In addition to diet therapy and exercise therapy as a prevention or treatment method for obesity, indigestible polysaccharides (dietary fiber) such as mannan have recently been introduced.
Attempts have been made to ingest it, but long-term use leads to a lack of not only major nutrients but also vitamins and minerals, making it unsatisfactory from a health perspective.

The inventors of the present application have searched for food ingredients that satisfy the necessary nutrients and make people slimmer, with the aim of suppressing or eliminating obesity, and as a result, they have focused on soybean ingredients. In ancient times, monks lived long lives and had fewer obese people because they had an appropriate calorie balance.
It is thought that the constant consumption of soybean products such as miso, tofu, and yuba contributed to the creation of a healthy and slim body.

Research has already been conducted on soybean protein regarding lipid metabolism, particularly its cholesterol-lowering effect, and it has been revealed that soybean protein is superior among vegetable proteins.

(For example, Fujimaki, Inoue, Kuninaka, Responsible Editor: Rice, Soybeans, and Fish)
(Published by Koseikan (1984)) Although it is unclear whether this is based on such academic grounds, recently, protein isolated from soybeans has been used for the purpose of alleviating obesity under the name protein. However, although these are usually taken in large amounts in place of meals or before meals, the current situation is that sufficient results have not been obtained.

Regarding amino acids that make up proteins, there is research by Professor Okuda of Ehime University, who has recognized that they have the effect of suppressing weight gain in obese animals. It was revealed that leucine, lysine, and valine) regulate the action of insulin in relation to lipid metabolism.

(e.g. Okuda, J., Biochem, 89,407
-410 (1981)) Soybean lecithin has already been recognized to have anticholesterolemic effects and to improve lipid metabolism, and is also used as a pharmaceutical. In addition, saponins were generally known to have only negative effects such as hemolysis and toxicity to fish, but recent research has shown that soybean saponins, adzuki bean, and carrot saponins have smaller hemolytic effects than other saponins. Positive effects of improving lipid metabolism, such as lipid antioxidant effects, were observed in vivo.

(For example, Kitayou, Yoshikawa, Chemistry and Biology 4e, 224 (1)
984)) For this reason, some people have recently been trying out soybean saponins for the purpose of suppressing obesity, but since saponins are special components that are only contained in small amounts in soybeans, they cannot be extracted or separated. It is a complicated and extremely expensive substance.

(Problems to be Solved by the Invention) Based on the above background, this invention was obtained as a result of repeated research on the anti-obesity effects of soybean protein, soybean lecithin, and soybean saponin.

The purpose is to propose an obesity-suppressing composition that can be taken in a small amount, which is reasonable for health and daily life, and which is economically less burdensome, and which can suppress or eliminate obesity.

(Means for Solving the Problems) The obesity-suppressing composition of the present invention is characterized by containing soybean protein and saponin as active ingredients, and having a weight ratio of soybean protein to saponin of 100:5 to 25. If the weight ratio of saponin to 100 parts of soybean protein is less than 5, the effect of saponin will be poor, and if it exceeds 25, the effect of saponin will approach saturation, and adding more than this will increase the cost, which is not preferable.

The soybean protein used in this invention can be selected from those obtained by conventional industrial means. It is usually used as a powder containing 90% or more of protein components.

Furthermore, soybean saponin is produced industrially using soybeans as a raw material by an extraction method using a solvent such as alcohol. It is usually used as a crude product with a saponin content of about 45% and approximately the same amount of oligosaccharide.

(Example) Next, animal experiments conducted to complete this invention will be described. Obese mice are created when mice are given gold thioglucose intraperitoneally and kept in a high-fat carbohydrate environment. Soybean protein, saponin, and lecithin were administered as test substances to these obese mice, zero weight gain was measured, and the obesity-suppressing effects of these substances were compared and studied.

(Experimental materials and experimental methods) The animal used was an ICR strain (♀) mouse, weighing approximately 20-25 g.
(5 to 7 weeks old) was purchased from Nippon Talea (■) and used after preliminary rearing for 5 to 7 days. Gold thioglucose (hereinafter referred to as GTG) was provided by SIGUMA (USA), and three test substances were provided by LICASMEYER (West Germany).

Purified soybean protein obtained industrially by an extraction method was used as the soybean protein. It is a pale yellow powder that contains more than 90% protein and has a slight odor and unique taste. An example of its amino acid composition is as follows.

g/100g g/100g
Alanine 4.1 Lysine 6.
3 Arginine 7.5 Methionine 1
．． 3 Aspartic acid 11.9 Phenylalanine 5.4 Cystine 1.3 Proline
5.5 Glutamic acid 18. O serine
5.2 Glycine 4.2 Threonine
3.7 histidine 2.6 tryptophan
1.5 Isoleucine 4.9 Tyrosine
4.0 Leucine 8.1 Valine
4.5 Saponin was obtained by extracting with alcohol etc. from soybeans. Pale yellow crude saponin with a concentration of 45% was used.

Lecithin is obtained industrially from soybeans, and is a yellow powder containing 97% or more of lecithin (acetone insoluble material), and has a slightly unique odor and taste.゛The composition of the mixed feed used in this experiment is as follows.

Casein 15% (weight) Corn starch 55% (weight) Corn oil 25% (weight) Salt m1xture 4% (weight) Mixed vitamins 1% (weight) Choline chloride (50%) 200■ Tested on compound feed containing 3000 IU or more of vitamin A The substances were mixed, administered to mice, and fed. GTG was intraperitoneally administered once in advance at 0.6 g/kg (body weight). The administration period of the test substance (experiment period) is 6
It was made into a week. During this period, body weight was measured once a week. In addition, obese mice to which GTG was administered and fed only a compound feed were used as a control group, and mice to which GTG was administered and fed to a compound feed containing the test substance were made to be a test group. 15 mice were used in each group.

For reference, GTG was not administered to the mice, and normal feed (
Oriental Yeast (manufactured by Oriental Yeast) was used as the normal mouse group.

(Left below) Experimental Example 1 Examination of the effects of single administration of soybean protein, soybean lecithin, and saponin Note 1: Group in which soybean protein was administered at 100 μ/kg (body weight) to mice.

Fist 2: Relative value for each group when the average weight gain rate of GTG obese obese horse mice after 6 weeks is set as 100.

-3: Saponin blunt equivalent dose. For example, saponin 12 indicates an administration of 25 μg/kg of crude saponin.

Experimental Example 2 Examination of the additive effects of the three components When 100 μg of protein, 50 μg of lecithin, and 12 μg of saponin, which are ineffective amounts when used alone, were administered in combination, the effect was as significant as the administration of 50 μg of saponin alone. It was found that there was a clear mutual effect. Also,
When the dose is increased, the effect tends to saturate.

(Left below) Experimental Example 3. Effectiveness of the additive effects seen in the three components divided into two components. From the results of Experimental Examples 1 and 2.3 above, soybean protein and saponin have no effect when administered alone. By administering ineffective doses in combination, a body weight suppressing effect was observed at a much lower dose (174 to 175 doses) than when administered alone.

Experimental Example 4 Weight Suppressing Effect in Clinical Cases, Weight Loss Test on Obese Humans Based on the results of animal experiments, a weight loss test was conducted in the United States on 30 obese humans with an average weight of 90 kg for the purpose of suppressing obesity. The test period was 1.5 to 2 months, and body weight and abdominal circumference were measured before and after administration of the test drug. During this period, no dietary guidance regarding calorie restriction was given. The amount of saponin in the test drug was approximately 173 0.5, which is the conventionally used amount.
■/kg was calculated and administered as follows.

That is, in Japan, the effective amount of saponin for humans is 50 to 1,000 cubic centimeters per day, and an effective dose of 100 cubic centimeters per day has been reported for an obese person with a normal body weight of 70 kg.

This is 1.42 μ/kg body weight, and in this clinical example, approximately 1/3 of that amount, 0.5 μ/kg, was administered depending on the subject's body weight. In addition, the dosage of soybean protein is generally 5 to 10 g/day for a person weighing 60 years old, or a large amount of 83 to 166 mg per day for a person weighing 60 years. A significantly lower amount was used. That is, according to the ratio of protein:saponin=100:12 used in animal experiments, 4 .mu./kg was used in combination with saponin.

As a control, a group administered with saponin (0.5 μ/)cg alone and a group administered with protein (4 μ/kg) alone were established for comparative study.

Looking at the average body weight before and after administration, a decrease of 4.8 kg (5.4%) was observed in the combination administration group, but no such decrease was observed in any of the control groups. Also, when looking at the average value of abdominal circumference, the combination treatment group had a mean value of 9.4a.
n (10.4%) decreased, whereas no major changes were observed in any of the control groups. It is understood that the combination administration works more effectively on abdominal circumference, which has a lot of fat, than on body weight, and is effective in reducing obesity.

The composition of the present invention containing soybean protein and saponin as active ingredients is a combination of purified soybean protein such as soybean protein and saponin such as crude saponin, and can be prepared as a powder or in the form of granules, tablets, or capsules. Can be used. It can also be added to processed foods such as sweets, breads, dairy products, and soy milk.

In the above examples, the composition was constructed using crude saponin with a saponin content of 45% and purified protein with a purified protein content of 90% or more, but the content is not limited to these. A lower content may also be used. In short, the amount used may be adjusted depending on the content of the active ingredient.

The ratio of saponin to soybean protein was 100:12 in the above example, but it is usually 100:5 to 2.
Used as a composition in the 5th range.

(Function) 100 parts by weight of soybean protein of this invention, 5 to 25 parts of saponin
In a composition containing parts by weight as active ingredients, the two ingredients are combined to exhibit a synergistic effect, and the intake amount is 1/3 or less of the effective amount of each ingredient that exerts the effect alone, that is, protein 4. ■/kg, saponin 0, 5 mg/
It exhibits a remarkable obesity-suppressing effect within a range of about 1.5 kg, which was previously considered to be an ineffective dose.

(Effects) This composition can have an obesity-suppressing effect with a small intake, and there are no health problems such as side effects or strain on daily life caused by a large intake. Furthermore, since the amount of expensive saponin is small, the economic burden is also small.

Procedural amendment Showa b1 January 29th

Claims (1)

[Claims] (1) An obesity-suppressing composition containing soybean protein and saponin as active ingredients, the weight ratio of soybean protein to saponin being 100:5 to 25.